Press releases
$3.4m Pharmacy Compounding Facility re-opens in Coorparoo, QLD
Friday, 30 November 2012: Today, the Hon. Lawrence Springborg, Queensland Minister for Health, officially opened the $3.4 million newly expanded and upgraded Baxter Healthcare compounding pharmacy in Queensland. Based in Coorparoo, the facility will supply a complete range of aseptically compounded IV preparations, including chemotherapy, analgesics, antibiotics and parenteral nutrition to more than 60 pharmacy customers in Queensland.
This investment by Baxter ensures continued supply to meet demand for compounded medications throughout Queensland over the next decade.
David Akeroyd, Managing Director of Baxter ANZ says: "Baxter has been manufacturing in Australia for nearly 50 years, working with government and our hospital partners to provide quality medications, manufactured in Therapeutic Goods Administration (TGA) - licensed facilities. This expansion is another sign of Baxter's commitment to supporting our customers, the healthcare industry and of course the people of Queensland."
"Compounding cancer medications and nutrition therapies has been a core competency for Baxter in Australia and New Zealand for close to 30 years, and the expansion and upgrade of the existing facility will allow us to service hospitals not only in Queensland but nationwide", said Akeroyd.
Baxter's supply of patient-specific antibiotics and nutrition solutions in ready-to-use formats, allows people to undertake treatment at home, thus reducing their hospital stays, reducing hospital costs and minimising hospital acquired infections.
Stephen Thompson, Baxter Healthcare ANZ Pharmacy Services Director says: "This facility produces over 150,000 individual products per annum, 85% of which are patient specific and dispatched within 24 hours of the order being placed. We deliver highly specialised products daily to both metropolitan and rural hospitals across Queensland. This service allows many rural patients to be treated closer to their own home rather than being forced to travel into a metropolitan centre."
Baxter's latest investment provides aseptic compounded drug therapy to both public and private hospitals, along with oncology centres across Queensland allowing patient needs to be met no matter where they are being treated.
